Embryo lethality and teratogenicity of a new fluoroquinolone antibacterial DW-116 in rats

Archives of Toxicology

Volumn 74, Issue 2, 2000, Pages 120-124

  Kim, Jong Choon ^a   Yun, Hyo In ^b   Shin, Ho Chul ^a   Han, Sang Seop ^a   Chung, Moon Koo ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

Embryolethal effect; Growth retardation effect; Maternal toxicity; Quinolone; Teratogenic effect

Indexed keywords

FANDOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN VENTRICLE DILATATION; CLEFT PALATE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; EDEMA; EMBRYO; EMBRYOTOXICITY; FEMALE; HEART VENTRICLE SEPTUM DEFECT; LETHALITY; LUNG HYPOPLASIA; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETON MALFORMATION; TERATOGENICITY; TOXICITY TESTING;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; BODY WEIGHT; BONE AND BONES; EATING; FEMALE; FETAL DEATH; FLUOROQUINOLONES; MALE; MATERNAL-FETAL EXCHANGE; PIPERAZINES; PREGNANCY; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS;

ANIMALIA;

EID: 0034066814     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002040050662     Document Type: Article

References (23)

1. Brown SA (1996) Fluoroquinolones in animal health. J Vet Pharmacol Ther 19: 1-14
2. Chernoff N, Rogers JM, Kavlock RJ (1989) An overview of maternal toxicity and prenatal development: considerations for developmental toxicity hazard assessments. Toxicology 59: 111-125
3. Choi KH, Hong JS, Kim SK, Yoon SJ, Choi EC (1997) In-vitro and in-vivo activity of DW-116, a new fluoroquinolone. J Antimicrob Chemother 39: 509-514
4. Christ W, Lehnert T (1990) Toxicity of the quinolones. In: Siporin C et al. (eds) The new generation of quinolones. Marcel Dekker, New York, pp. 165-187
5. Clement JJ, Burres N, Jarvis K, Chu DTW, Swiniarski J, Alder J (1995) Biological characterization of a novel antitumor quinolone. Cancer Res 55: 830-835
6. Davis GJ, Mckenzie BE (1989) Toxicologic evaluation of ofloxacin. Am J Med 87: 43S-46S
7. Ebisuno S, Inagaki T, Kohjimoto Y, Ohkawa T (1997) The cytotoxic effects of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer 80: 2263-2267
8. Han KO, Hwang YH, Lee WY, Chung YH, Yoon SJ, Lee DK (1995) In vitro and in vivo activity of DW-116, a new quinolone antibiotic. 35th Intersci Conf Antimicrob Agents Chemother F193(AbSt)
9. Hooper DC, Wolfson JS (1993) Adverse effects. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents. American Society of Microbiology, New York, pp 489-512
10. Hwang YH, Han KO, Lee J, Yang HB, Chung YH, Yoon SJ, Lee DK (1997) In vitro and in vivo antibacterial activity of DW-116, a new quinolone antibiotic. J Appl Pharmcol 5: 187-193
11. Johnson EM, Christian MS, Dansky L, Gabel BEG (1987) Use of the developmental relationship in prescreening for developmental hazards. Teratogen Carcinogen Mutagen 7: 273-285
12. Karabalut N, Drusano GL (1993) Pharmacokinetics of the quinolone antibacterial agents. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents. American Society of Microbiology, New York, pp 195-223
13. Lee DK (1995) Pharmacokinetic study of a new quinolone, DW-116. Drugs 49: 323-325
14. Morinaga T, Fujii S, Furukawa S, Kikumori M, Yasuhira K, Shindo Y, Watanabe M, Sumi N (1996) Reproductive and developmental toxicity studies of prulifloxacin (NM441)(2) - a teratogenicity study in rats by oral administration. J Toxicol Sci 21: 187-206
15. Neu HC (1992) Quinolone antimicrobial agents. Annu Rev Med 43: 465-486
16. Norrby SR (1991) Side effects of quinolone: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 10: 378-383
17. Park YH, Jung BH, Chung BC, Park J, Mitoma C (1997) Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. Drug Metabol Dispos 25: 1101-1103
18. Seay TM, Peretsman PS, Dixon PS (1996) Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 155: 757-762
19. von-Rosenstiel N, Adam D (1994) Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs 47: 872-901
20. Watanabe T, Fujikawa K, Harada S, Ohura K, Sasaki T, Takayama S (1992) Reproductive toxicity study of new quinolone antibacterial agent levofloxacin in rats and rabbits. Arzneim Forsch 43: 374-377
21. Wolfson JS, Hooper DC (1991) Overview of fluoroquinolone safety. Am J Med 91: 153S-161S
22. Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H (1992) Antitumor quinolone with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 52: 2818-2822
23. Yu IL, Chung SJ, Lee MH, Shim CK (1997) Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats. J Pharmacol Sci 86: 550-553